The company reported revenue of over C$7.8 million for the three month period that ended on March 31. In its revenue breakdown, CannTrust indicated dried cannabis managed to create over C$3 million, while extracts brought C$4,477,526.
CannTrust explained due to using the grow rooms from its Langstaff facility to harvest the mother plants for its brand new Niagara Greenhouse space, the company was required to purchase product from other cannabis producers in order to meet the demand for its products.
“Multiple harvests have now been completed at the Niagara Greenhouse Facility and these temporary third-party product purchases have now been replaced with home grown product,” the company said.
The reach of CannTrust’s products has increased since the active patient base for the company grew to over 40,000. During the quarter, the company sold 982,269 grams of cannabis.
According to the report, CannTrust has increased the expectations for the Niagara facility production capacity from 40,000 to 50,000 kilograms annually.
Optimistic outlook thanks to future production from Niagara facility
In a research note issued on Tuesday, Echelon Wealth Partners analyst Russell Stanley maintained his “Speculative Buy” rating on the company and set their one-year price target at C$18.50.
Despite falling short of his estimates, the company incurred one-time costs that, if taken away, would make its earnings before interest, tax, depreciation and amortization (EBITDA) on par with what Stanley had predicted.
“Given our view that dried cannabis will become increasingly commoditized, investors should favor companies that can develop and commercialize higher value products and/or deliver ultra-low production costs,” Stanley wrote.
The analyst wrote he expects the Niagara facility to provide a “meaningful contribution” to the company during the next quarter. This facility is also expected to have a phase two expansion, which Stanley wrote remains on track for mid-2018 completion.
During Tuesday’s trading hours, shares of TRST decreased 3.40 percent to reach C$9.66 per share. According to data from Yahoo! Finance, since joining the TSX, CannTrust’s share price has increased 7.22 percent in value, indicating a C$0.65 gain for investors.
On the research analysts data site aggregator TipRanks, CannTrust currently has a “Moderate Buy” rating thanks to the opinion from two analysts. The one-year price target for TRST is C$17.25.
As part of the Investing News Network (INN) cannabis outlook for Q12018, a portfolio manager with Redwood Asset Management Greg Taylor said he was surprised the move from CannTrust to dump its US assets and move its stock to the TSX didn’t have a larger impact.
“Once this move was made, the TRST was uplisted to the TSX which I thought would be a major positive and the stock would see a re-rating higher,” Taylor told INN. “But it didn’t seem to be noticed by the market.”
Despite providing a moderately successful quarter, the nature of the cannabis industry has sparked conversations of acquisitions with most enterprises.
More than the singularity of today’s gains, with MedReleaf officially taken out, CannTrust becomes the clear #1 prime asset in the lucrative medicinal market. With Aurora Cannabis establishing outright dominance, the odds of another suitor making an offer increase—and this should put a floor under the share price. The stock hasn’t been rising on a multi-day basis without reason.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.